HomeCompareOPHLY vs CHD

OPHLY vs CHD: Dividend Comparison 2026

OPHLY yields 3.41% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OPHLY wins by $782.55M in total portfolio value
10 years
OPHLY
OPHLY
● Live price
3.41%
Share price
$5.29
Annual div
$0.18
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$782.58M
Annual income
$740,792,960.47
Full OPHLY calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — OPHLY vs CHD

📍 OPHLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPHLYCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPHLY + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OPHLY pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPHLY
Annual income on $10K today (after 15% tax)
$289.50/yr
After 10yr DRIP, annual income (after tax)
$629,674,016.40/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, OPHLY beats the other by $629,672,909.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPHLY + CHD for your $10,000?

OPHLY: 50%CHD: 50%
100% CHD50/50100% OPHLY
Portfolio after 10yr
$391.30M
Annual income
$370,397,131.56/yr
Blended yield
94.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

OPHLY
Analyst Ratings
2
Sell
Consensus: Sell
Altman Z
5.0
Piotroski
8/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPHLY buys
0
CHD buys
0
No recent congressional trades found for OPHLY or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPHLYCHD
Forward yield3.41%1.28%
Annual dividend / share$0.18$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%23.1%
Portfolio after 10y$782.58M$26.4K
Annual income after 10y$740,792,960.47$1,302.64
Total dividends collected$779.53M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusSellBuy

Year-by-year: OPHLY vs CHD ($10,000, DRIP)

YearOPHLY PortfolioOPHLY Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$11,381$681.17$10,857$157.30+$524.00OPHLY
2$13,627$1,449.07$11,814$196.49+$1.8KOPHLY
3$17,824$3,243.01$12,887$245.97+$4.9KOPHLY
4$27,000$7,928.61$14,097$308.68+$12.9KOPHLY
5$51,340$22,449.56$15,473$388.49+$35.9KOPHLY
6$134,722$79,788.74$17,046$490.55+$117.7KOPHLY
7$535,510$391,357.72$18,861$621.76+$516.6KOPHLY
8$3,480,692$2,907,695.93$20,973$791.47+$3.46MOPHLY
9$39,050,210$35,325,869.63$23,454$1,012.51+$39.03MOPHLY
10$782,576,685$740,792,960.47$26,398$1,302.64+$782.55MOPHLY

OPHLY vs CHD: Complete Analysis 2026

OPHLYStock

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Full OPHLY Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this OPHLY vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPHLY vs SCHDOPHLY vs JEPIOPHLY vs OOPHLY vs KOOPHLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.